A pilot study of the effect of methotrexate or combined oral contraceptive on bleeding patterns after induction of abortion with mifepristone and a prostaglandin pessary.
Although a combination of mifepristone and a prostaglandin is a safe, acceptable alternative to vacuum aspiration for inducing abortion in early pregnancy, the longer period of vaginal bleeding after medical abortion is a disadvantage. The present study investigated whether administration of the combined oral contraceptive pill (COC) or the injection of methotrexate at the time of abortion would shorten the period of vaginal bleeding after medical abortion. After having a medical abortion induced with mifepristone (200 mg) and 0.5 mg gemeprost pessary, 80 women were randomized to four groups of 20 women each; Group A, COC; Group B, control; Group C, 50 mg/m2 methotrexate; and Group D, placebo injection. There was no significant difference in the duration of bleeding between Groups A and B (median 14 and 17 days) or between Groups C and D (18 and 15 days), or in the amount of bleeding (4 days of heavy bleeding in each group). The first period occurred sooner in Group A who took the COC (median/range: 25/15-54 control group versus 32/16-46 days, p < 0.04). The administration of methotrexate was associated with a temporary elevation in liver enzyme concentration in one woman. It is concluded that women who wish to use COC can start immediately after medical abortion. Addition of methotrexate after abortion has no significant beneficial effect on patterns of bleeding and cannot be recommended.
Martin
C W
CW
Department of Obstetrics and Gynaecology, University of Edinburgh, Scotland.
Brown
A H
AH
Baird
D T
DT
D000019:Abortifacient Agents; D000028:Abortion, Induced / Q000009:adverse effects*; D000328:Adult; D001772:Blood Cell Count; D003277:Contraceptives, Oral, Combined / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects; D008727:Methotrexate; D015735:Mifepristone; D010570:Pessaries; D011247:Pregnancy; D011453:Prostaglandins / Q000008:administration & dosage / Q000627:therapeutic use*; D014592:Uterine Hemorrhage / Q000188:drug therapy* / Q000209:etiology
D000019:Abortifacient Agents; D003277:Contraceptives, Oral, Combined; D011453:Prostaglandins; D015735:Mifepristone; D008727:Methotrexate